Prof Fabrice André speaks with ecancer at ESMO 2018 in Munich about results from a trial to treat advanced breast cancer with fluvestrant and targeted PI3Ka inhibitor alpelisib. He describes how alpelisib differs from other PI3K inhibitors as it...
Original Article: Results from the SOLAR-1 trial for advanced breast cancer